Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma

Ting Wang, Laura M. Fox, Desuo Wang

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


MS23 is a vasodilator with unique dual action pharmacological profile to inhibit type 4 PDE and antagonize L-type calcium channels. We validated an analytical protocol for MS23 in rat plasma using high performance liquid chromatography (HPLC). A C18 column and a phosphate/acetonitrite buffer were used for chromatographic separation. UV detection was performed at 307 nm. The calibration curve for MS23 was linear in the range from 50 to 10,000 ng/ml. The limit of quantification (LOQ) was 50 ng/ml. The results demonstrate that the method has linearity (R = 0.9989), specificity, and acceptable precision/accuracy. This method is simple, economic, and sufficient for in vivo pharmacokinetic studies on the compound.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Issue number1
StatePublished - Jan 2 2006


  • Antihypertensive
  • Calcium channel antagonist
  • Dual action
  • MS23
  • PDE4 inhibitor
  • Validation

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Clinical Biochemistry
  • Cell Biology


Dive into the research topics of 'Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma'. Together they form a unique fingerprint.

Cite this